Important Information for Pacira BioSciences, Inc. Investors: Deadline Reminder for Securities Class Action Lawsuit
New York, NY and New Orleans, LA – Kahn Swick & Foti, LLC (“KSF”) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”).
Background on the Lawsuit
The lawsuit alleges that Pacira BioSciences, Inc. made false and/or misleading statements and/or failed to disclose material information during the Class Period, violating securities laws. Specifically, the lawsuit alleges that the Company made false and/or misleading statements and/or failed to disclose that:
- There were issues with the commercialization of the Company’s SABER® Wound System;
- The Company’s financial results would be negatively impacted;
- The Company’s internal controls over financial reporting were weak;
- The Company’s revenue growth was due in part to improper revenue recognition.
Impact on Individual Investors
If you purchased Pacira BioSciences, Inc. securities during the Class Period, you may be able to recover your losses in the securities class action lawsuit. The lead plaintiff will act on behalf of all other class members in the lawsuit. The lead plaintiff will seek to appoint a law firm to represent the class. The lead plaintiff and the class representatives may select a law firm of their choice. An investor’s ability to share in any recovery is not dependent on serving as the lead plaintiff.
Impact on the World
The securities class action lawsuit against Pacira BioSciences, Inc. is significant because it highlights the importance of accurate and transparent financial reporting. Companies that provide false or misleading information to investors can face serious consequences, including legal action and damage to their reputation. This lawsuit also serves as a reminder to investors to carefully research companies before investing and to be aware of potential red flags.
Conclusion
If you purchased Pacira BioSciences, Inc. securities during the Class Period and believe you may have lost money as a result of the Company’s alleged securities law violations, you have until March 14, 2025 to file a lead plaintiff application in the securities class action lawsuit. KSF urges you to contact KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., to discuss your legal rights and potential recovery. You may also visit
This communication should not be construed as legal advice. It is for informational purposes only. Although the information contained herein is believed to be accurate, neither KSF nor the author makes any representation or warranty, express or implied, with respect to the timeliness or accuracy of this document or the information contained herein. Certain information in this notice may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, included herein may constitute forward-looking statements, including statements regarding the potential or alleged value or recovery of securities of Pacira BioSciences, Inc.
